1,340
Participants
Start Date
May 25, 2022
Primary Completion Date
July 17, 2022
Study Completion Date
April 7, 2024
NVX-CoV2515
Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).
NVX-Cov2373
Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
NVX-CoV2373 + NVX-CoV2515
Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
NVX-CoV2540
Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
NVX-CoV2373 + NVX-CoV2540
Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
Holdsworth House Medical Practice, Sydney
Emeritus Research, Botany
Australian Clinical Research Network (ACRN), Maroubra
Northern Beaches Clinical Research, Brookvale
Paratus Clinical Research Western Sydney, Blacktown
Novatrials, Newcastle
Paratus Clinical Research Central Coast, Kanwal
AIM Centre (Hunter Diabetes Centre), Merewether
Paratus Clinical Research Canberra, Bruce
Emeritus Research, Camberwell
Eastern Health-Box Hill Hospital, Box Hill
Monash Health -Monash Medical Centre, Melbourne
University Hospital Geelong-Barwon Health, Geelong
Paratus Clinical Research Brisbane, Albion
Core Research Group Pty Ltd, Milton
Data Health Australia PTY Ltd t/a Austrials, Taringa
AusTrials Wellers Hill, Wellers Hill
Griffith University Clinical Trial Unit, Southport
Clinical Medical and Analytical Excellence (CMAX), Adelaide
Lead Sponsor
Novavax
INDUSTRY